Targeted Therapies Have Most Clinically Useful Biomarker Labeling
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Pharmacogenetic biomarkers for molecularly targeted therapies are supported by considerably better evidence that they improve patient outcomes than biomarkers in labeling of untargeted drugs, but a JAMA study still found that half of biomarkers in label lacked convincing evidence of clinical utility.